CPS improves the behavioral deficits in pole tests and gait tests. CPS-treated mice exhibited significant improvement in landing time. Treatment with CPS prevented the decrease in the length of stride. It was found that CPS decreases the reduction of tyrosine hydroxylase, dopamine, and its metabolites within the PD model to prevent DA neuron death. In addition, CPS inhibits the inflammatory process in the central and peripheral nervous systems. CPS enhanced the gut immune system by increasing DAO and S-IgA activities within the MPTP-induced PD model. The gene discussed is CD79A; the disease is Parkinson disease.